The antimicrobial mechanisms of action of probiotics are diverse and include immunologic and non-immunologic responses, and also direct effects on the pathogens. A dilemma posed to probiotic-based vaccines is that some species of microbes have beneficial, but also pathogenic strains, and therefore, the use of the beneficial strains will raise safety concerns. For instance, Enterococcus faecalis strain CECT 7121 has a direct larvicide effect on T. canis larvae but regulatory bodies may not accept a probiotic comprising E. faecalis because many pathogenic strains are known for this bacterium. Likewise, the protective role of α-Gal against malaria was related to an Escherichia coli strain for which pathogenic strains also exist. Nevertheless, probiotics include several microorganisms, mostly within Lactobacillus or Bifidobacterium genera. Interestingly, gut colonization by the human gut pathobiont E. coli O86:B7, but not by the probiotic L. casei, induce an increase in the levels of anti-α-Gal-specific IgG and IgM. Apparently, both E. coli O86:B7 and L. casei contain α-Gal on their surfaces. In addition, Dahl et al. showed that even when the α-Gal epitope is highly represented in different enterobacteria of the gut microbiota of α-Gal knockout mice, no response to this antigen was induced without previous immunization. This raises the question whether all probiotic bacteria expressing α-Gal are able to induce a protective anti-α-Gal antibody response. Importantly, the expression of α-Gal by members of the family Enterobacteriaceae (Gram-negative bacteria, e.g. E. coli spp.) is mainly associated with the bacterial capsule and cell wall glycoproteins, as well as with carbohydrate units of bacterial lipopolysaccharide (LPS). However, Lactobacillus spp. are Grampositive bacteria and do not produce LPS. Likewise, other E. coli spp. such as E. coli K2 strain may not produce α-Gal. The association of α-Gal to highly immunogenic components such as LPS in the membrane of pathogenic bacteria like E. coli O86:B7 may have a major impact in the immune response elicited against this antigen. To overcome this difficulty, beneficial probiotic species expressing α-Gal may be combined with adjuvants such as toll-like receptors (TLRs). TLRs are pattern recognition receptors expressed by various cells of the gastrointestinal track, including epithelial and immune cells. Differential activation of TLRs by microbiota or invading pathogens may contribute to intestinal homeostasis or to the initiation of inflammatory responses, respectively. It is well known that LPS is a specific activator of TLR4. TLR4 agonists such as LPS induce the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling, which elicit a pro-inflammatory cytokine production. TLR4 activation is also associated to increased intestinal permeability and enhanced bacterial translocation to inner lamina. In contrast, activation of TLR9 by unmethylated CpG motifs in intestinal epithelial cells suppresses NF-kB-induced proinflammatory cytokine production and contributes to intestinal homeostasis. Lactobacillus spp. DNA, which is rich in unmethylated CpG motifs, was shown to activate TLR9, inducing a tolerogenic and anti-allergic immune response in the gut. Although not necessarily related to the anti-α-Gal immune response, recently Villarino et al. showed that the composition of the gut microbiota is a risk factor for severe malaria. They provided evidence that abundance increase of Lactobacillus and Bifidobacterium in the gut flora is associated with resistance to malaria in mice and proposed the modulation of the gut microbiota using probiotics as a potential intervention to reduce malaria severity. In the context of the increasing burden of emerging VBDs worldwide, we propose the use of probiotics composed of bacteria producing the carbohydrate α-Gal as dietary supplements to control VBDs. Although previous studies have shown that anti-α-Gal antibodies in human serum do not induce 100% killing of Plasmodium, the use of probiotics containing bacteriaproducing α-Gal may alter host natural response to this carbohydrate resulting in increased protection to parasite infection. Considering the results of previous studies, while probiotics such as Lactobacillus spp. may constitute the appropriate carrier of α-Gal in probiotic-based vaccines against vector-borne pathogens, the combination with TLR4 agonists may be needed to develop a potent and protective immune response against this carbohydrate. Future studies should focus on the characterization of the mechanisms involved in the immune response to α-Gal. This antibody response may be effective against different vector-borne pathogens that contain α-Gal on their surface. Therefore, the probiotics-based vaccines exploiting this major evolutionary adaptation may constitute an effective strategy to reduce the impact of VBDs on human health. Although the road to probiotic-based vaccines appears to be challenging, the rational design of vaccines exploiting the special immunity of human to α-Gal may be our best strategic move to win our battle against VBDs.
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